Nasopharyngeal CarcinomaPhase 2NCT07555860
Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
A Phase 2 study testing Becotatug Vedotin, Toripalimab and Camrelizumab in people with Nasopharyngeal Carcinoma, run by Sun Yat-sen University.
Trial summary
This exploratory clinical study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma to receive two cycles of becotatug vedotin plus a PD-1 monoclonal antibody, followed by sequential radiotherapy and PD-1 monoclonal antibody maintenance until disease progression or unacceptable toxicity. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Nasopharyngeal Carcinoma
- What is being tested?
- Becotatug Vedotin, Toripalimab and Camrelizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- No sites listed yet
- Study dates
- 20 Apr 2026to 31 Dec 2029
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntarily participates in the study and provides written informed consent.
- Aged 18-70 years, male or non-pregnant female, with an expected survival of ≥3 months and an ECOG performance status of 0 or 1.
- Histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma, differentiated or undifferentiated carcinoma, corresponding to WHO type II or III, with clinical stage rT2-4N0-3M0, rIA-III according to the AJCC 9th edition.
- Recurrence occurring more than 12 months after completion of initial radiotherapy, with no systemic or local antitumor treatment during this interval.
- At least one measurable lesion according to RECIST v1.1.
- Hemoglobin ≥90 g/L, white blood cell count ≥4.0 × 10⁹/L, and platelet count ≥100 × 10⁹/L.
Show all 10Show fewer
- Adequate liver function: total bilirubin <2.0 × ULN; AST and ALT ≤2.5 × ULN in the absence of liver metastasis, or ALT or AST ≤3.0 × ULN in the presence of liver metastasis; ALP ≤1.5 × ULN, or ≤2 × ULN in the presence of liver metastasis; serum albumin ≥30 g/L.
- Adequate coagulation function: INR or PT and APTT ≤1.5 × ULN, except for patients receiving anticoagulant therapy, whose anticoagulation level should be within the therapeutic range. These laboratory parameters should be closely monitored by the investigator if the patient is receiving anticoagulant therapy.
- Adequate renal function, defined as serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min if serum creatinine is >1.5 × ULN. Creatinine clearance should be calculated using the corrected Cockcroft-Gault formula.
- Female and male patients of childbearing potential must agree to use adequate contraception during treatment and for 180 days after the last dose.
Who cannot join
- Patients with surgically resectable locally recurrent disease, including rT2 disease limited to the superficial parapharyngeal space and located more than 0.5 cm from the internal carotid artery, or rT3 disease limited to the floor of the sphenoid sinus and located more than 0.5 cm from the internal carotid artery and cavernous sinus.
- Nasopharyngeal necrosis, radiation-induced brain injury, severe cervical fibrosis, or other CTCAE v5.0 Grade ≥3 radiation-related complications, with extremely high radiotherapy risk as assessed by the investigator.
- Grade ≥2 peripheral neuropathy according to CTCAE v5.0.
- Receipt of systemic chemotherapy within 3 weeks before the first dose of study drug; small-molecule targeted therapy within 2 weeks or 5 half-lives, whichever is longer, before the first dose; antitumor biologic therapy, macromolecular targeted therapy, immunotherapy, or major surgery within 4 weeks before the first dose, except for minor surgery within 2 weeks with complete recovery.
- Residual toxicity from prior antitumor therapy, including immunotherapy, targeted therapy, chemotherapy, or radiotherapy, except alopecia, fatigue, and Grade 2 hypothyroidism, or clinically significant laboratory abnormalities greater than Grade 1 according to CTCAE v5.0.
- Uncontrolled or poorly controlled cardiac disease, including congestive heart failure (CHF) Grade ≥2 according to CTCAE v5.0 or New York Heart Association classification, myocardial infarction, unstable angina, history of ventricular tachycardia or torsades de pointes, or arrhythmia requiring treatment within 6 months before enrollment; QTcF >450 ms in males or >470 ms in females; complete left bundle branch block; or third-degree atrioventricular block. QTcF = QT/(RR^0.33).
Show all 20Show fewer
- Pulmonary embolism or deep vein thrombosis within 3 months before the first dose of study drug, except catheter-related thrombosis from an infusion port or PICC line.
- Known history of malignancy, except for radically treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, carcinoma in situ, or papillary thyroid carcinoma, unless the patient has received potentially curative treatment and has had no disease recurrence within 5 years after treatment initiation.
- Any severe or uncontrolled systemic disease, including uncontrolled or poorly controlled hypertension, such as systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg, or diabetes mellitus with HbA1c >8%.
- Active bleeding, history of coagulation disorder, or treatment with coumarin anticoagulants.
- Known hypersensitivity to any component or excipient of becotatug vedotin, including citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80; or known Grade ≥3 hypersensitivity reaction to prior anti-EGFR drugs, including investigational study drugs, or other monoclonal antibodies.
- Known active hepatitis B or hepatitis C. Active hepatitis B is defined as known HBsAg positivity and HBV DNA ≥500 IU/mL. Active hepatitis C is defined as known hepatitis C antibody positivity and quantitative HCV RNA above the lower limit of detection. Other severe liver diseases, including chronic autoimmune liver disease, primary biliary cirrhosis or sclerosing cholangitis, alcoholic liver disease, or nonalcoholic steatohepatitis (NASH), are also excluded.
- Severe uncontrolled infection; known human immunodeficiency virus (HIV) infection with positive HIV antibody; diagnosis of acquired immunodeficiency syndrome (AIDS); active autoimmune disease, except type 1 diabetes mellitus, hypothyroidism controlled by replacement therapy, and skin diseases not requiring systemic therapy, such as vitiligo, psoriasis, or alopecia; prior allogeneic tissue or organ transplantation, stem cell or bone marrow transplantation, or prior solid organ transplantation.
- Active bacterial, viral, fungal, rickettsial, or parasitic infection requiring systemic anti-infective therapy, unless treated and resolved before study drug administration.
- Receipt of a live viral vaccine within 30 days before the first dose of study drug.
- History of or concurrent interstitial pneumonia, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm, or similar pulmonary conditions.
- Receipt of immunology-based therapy for any reason, including chronic systemic steroid therapy equivalent to >10 mg/day prednisone within 7 days before the first dose of study drug or at any time during the study. Inhaled or topical steroids, systemic corticosteroids equivalent to ≤10 mg/day prednisone, and short-term corticosteroids equivalent to >10 mg/day prednisone, such as premedication before contrast administration, are permitted.
- Uncontrolled pleural, abdominal, pelvic, or pericardial effusion requiring drainage at least once per month.
- Positive pregnancy test or breastfeeding. Female and male patients who do not plan to use adequate contraception during treatment and for 180 days after the last dose are excluded.
- Any other disease, clinically significant laboratory abnormality, severe medical or psychiatric condition, or substance abuse including alcoholism that, in the investigator's opinion, may compromise patient safety, study integrity, patient participation, or interfere with the study objectives and outcome analysis.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: An Open-Label, Single-Arm, Single-Center Phase II Study of Induction Becotatug Vedotin Plus a PD-1 Inhibitor Followed by Radiotherapy With PD-1 Maintenance in Patients With Unresectable Locally Recurrent Nasopharyngeal Carcinoma
This exploratory clinical study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma to receive two cycles of becotatug vedotin plus a PD-1 monoclonal antibody, followed by sequential radiotherapy and PD-1 monoclonal antibody maintenance until disease progression or unacceptable toxicity. The study aims to evaluate the efficacy and safety of this treatment strategy.
Read the detailed description
Detailed Description
This is an open-label, single-arm, single-center Phase II clinical study. The study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma. Eligible patients will receive two cycles of induction therapy with becotatug vedotin plus a PD-1 monoclonal antibody, followed by intensity-modulated radiotherapy. During and after radiotherapy, patients will continue PD-1 monoclonal antibody maintenance treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria.
The study is designed to evaluate the efficacy and safety of this sequential treatment strategy. The primary endpoint is objective response rate assessed by RECIST v1.1. Secondary endpoints include locoregional recurrence-free survival, progression-free survival, distant metastasis-free survival, 12-month and 24-month progression-free survival rates, overall survival, disease control rate, duration of response, treatment-related adverse events assessed according to NCI-CTCAE v5.0, and quality of life.
- Conditions
- Nasopharyngeal Carcinoma
- Being tested
- Becotatug Vedotin, Toripalimab, Camrelizumab, Intensity-Modulated Radiotherapy
- Medical subject headings
- Nasopharyngeal Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Becotatug VedotinDrug
Becotatug vedotin will be administered at 2.0 mg/kg intravenously on Day 1 every 3 weeks for 2 cycles as induction therapy, in combination with a PD-1 monoclonal antibody.
ToripalimabDrug
Toripalimab will be administered at 240 mg intravenously on Day 1 every 3 weeks. Toripalimab is one of the optional PD-1 monoclonal antibodies in this study and will be used as an alternative to camrelizumab, not in combination with camrelizumab. It will be given during induction therapy, concurrently with radiotherapy, and as maintenance therapy after radiotherapy until disease progression or unacceptable toxicity.
CamrelizumabDrug
Camrelizumab will be administered at 200 mg intravenously on Day 1 every 3 weeks. Camrelizumab is one of the optional PD-1 monoclonal antibodies in this study and will be used as an alternative to toripalimab, not in combination with toripalimab. It will be given during induction therapy, concurrently with radiotherapy, and as maintenance therapy after radiotherapy until disease progression or unacceptable toxicity.
Intensity-Modulated RadiotherapyDrug
Intensity-modulated radiotherapy will be delivered once daily, 5 days per week. Prescribed doses are 60 Gy in 27 fractions to PTVnx, 60-64 Gy in 27 fractions to PTVnd, and 54 Gy in 27 fractions to PTV1.
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | Becotatug Vedotin Plus PD-1 Monoclonal Antibody Induction Followed by Radiotherapy With Concurrent and Maintenance PD-1 Monoclonal Antibody Receives: Drug: Becotatug Vedotin; Drug: Toripalimab; Drug: Camrelizumab; Drug: Intensity-Modulated Radiotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective response rate
The proportion of participants who achieve a complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST v1.1, from the first dose until disease progression, initiation of new anticancer therapy, death, or the last tumor assessment, whichever occurs first.
Measured: Baseline; end of 2 induction cycles (21 days/cycle); 8-12 weeks after radiotherapy; every 12 weeks through Month 24; then every 24 weeks thereafter until progression, new anticancer therapy, death, or study completion, up to 36months.
Secondary outcomes (10)
Duration of Response (DoR)
For participants who achieve a confirmed complete response (CR) or partial response (PR), duration of response is defined as the time from the first documented CR or PR to the first documented disease progression or death from any cause, whichever occurs first.
Measured: From first documented CR or PR until first documented disease progression or death, whichever occurs first, assessed up to 36 months.
Locoregional Recurrence-Free Survival (LRFS)
Locoregional recurrence-free survival is defined as the time from the first dose to the first documented locoregional recurrence/progression or death from any cause, whichever occurs first.
Measured: From the first dose until the first documented locoregional recurrence/progression or death from any cause, whichever occurs first, assessed up to 36 months.
Treatment-Related Adverse Events
Treatment-related adverse events will be assessed and graded according to NCI-CTCAE v5.0. The incidence and severity of adverse events, Grade 3 or higher adverse events, serious adverse events, and adverse events leading to dose modification, treatment interruption, or treatment discontinuation will be summarized.
Measured: From first dose to 90 days after last study treatment; late radiotherapy-related toxicities followed until Month 24 or study completion.
Overall Survival (OS)
OS is defined as the time from the first dose to death from any cause. Participants who are alive will be censored at the date of last confirmed survival status.
Measured: From the first dose until death from any cause, assessed up to 36 months.
12-Month Progression-Free Survival Rate
The 12-month PFS rate is defined as the proportion of participants who remain alive and progression-free at 12 months, estimated using the Kaplan-Meier method based on PFS.
Measured: From the first dose to 12 months.
24-Month Progression-Free Survival Rate
The 24-month PFS rate is defined as the proportion of participants who remain alive and progression-free at 24 months, estimated using the Kaplan-Meier method based on PFS.
Measured: From the first dose to 24 months.
Progression-Free Survival (PFS)
Progression-free survival is defined as the time from the first dose to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
Measured: From the first dose until the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first, assessed up to 36 months.
Disease Control Rate (DCR)
The proportion of participants who achieve a best overall response of complete response (CR), partial response (PR), or stable disease (SD), as assessed by the investigator according to RECIST version 1.1.
Measured: Baseline; end of 2 induction cycles (21 days/cycle); 8-12 weeks after radiotherapy; every 12 weeks through Month 24; then every 24 weeks thereafter until progression, death, or study completion, up to 36 months.
Distant Metastasis-Free Survival (DMFS)
DMFS is defined as the time from the first dose to the first documented distant metastasis or death from any cause, whichever occurs first. Distant metastasis will be assessed by imaging examinations, including chest CT, abdominal imaging, bone scan, PET/CT, or other clinically indicated examinations.
Measured: From first dose until first documented distant metastasis or death, whichever occurs first, assessed up to 36 months.
Quality of Life (QoL)
Quality of life will be assessed using the EORTC QLQ-C30 questionnaires. Scores for each domain and health status will be calculated according to the questionnaire scoring manuals, and changes from baseline will be summarized.
Measured: Baseline; end of 2 induction cycles (21 days/cycle); end of radiotherapy; 8-12 weeks after radiotherapy; every 12 weeks through Month 24; then every 24 weeks thereafter until study completion, up to 36 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start20 Apr 2026 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nasopharyngeal CarcinomaStudies of the same condition, open and under way.
- More trials run by Sun Yat-sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Cancer
- Masking
- None (open label)
- Enrolment
- 28 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, YiJun Hua, Sun Yat-sen University
- Investigators
- Yi-Jun Hua, MD, Principal investigator, Sun Yat-sun University Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07555860
- Sponsor's protocol ID
- 2025-FXY-540-NPC
- Status last verified
- Apr 2026
- First submitted
- 14 Apr 2026
- Last updated
- 29 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Researchers who has been approved can share.
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Single-Arm, Single-Center Phase II Study of Induction Becotatug Vedotin Plus a PD-1 Inhibitor Followed by Radiotherapy With PD-1 Maintenance in Patients With Unresectable Locally Recurrent Nasopharyngeal Carcinoma
- ClinicalTrials.gov ID
- NCT07555860
- Acronym / sponsor ID
- 2025-FXY-540-NPC
- Conditions
- Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 28 participants (estimated)
- Lead sponsor
- Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- 20 Apr 2026 (estimated)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This exploratory clinical study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma to receive two cycles of becotatug vedotin plus a PD-1 monoclonal antibody, followed by sequential radiotherapy and PD-1 monoclonal antibody maintenance until disease progression or unacceptable toxicity. The study aims to evaluate the efficacy and safety of this treatment strategy.
Detailed description
Detailed Description
This is an open-label, single-arm, single-center Phase II clinical study. The study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma. Eligible patients will receive two cycles of induction therapy with becotatug vedotin plus a PD-1 monoclonal antibody, followed by intensity-modulated radiotherapy. During and after radiotherapy, patients will continue PD-1 monoclonal antibody maintenance treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria.
The study is designed to evaluate the efficacy and safety of this sequential treatment strategy. The primary endpoint is objective response rate assessed by RECIST v1.1. Secondary endpoints include locoregional recurrence-free survival, progression-free survival, distant metastasis-free survival, 12-month and 24-month progression-free survival rates, overall survival, disease control rate, duration of response, treatment-related adverse events assessed according to NCI-CTCAE v5.0, and quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Cancer
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Drug: Becotatug Vedotin, Drug: Toripalimab, Drug: Camrelizumab, Drug: Intensity-Modulated RadiotherapyBecotatug Vedotin Plus PD-1 Monoclonal Antibody Induction Followed by Radiotherapy With Concurrent and Maintenance PD-1 Monoclonal Antibody |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Voluntarily participates in the study and provides written informed consent.
- Aged 18-70 years, male or non-pregnant female, with an expected survival of ≥3 months and an ECOG performance status of 0 or 1.
- Histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma, differentiated or undifferentiated carcinoma, corresponding to WHO type II or III, with clinical stage rT2-4N0-3M0, rIA-III according to the AJCC 9th edition.
- Recurrence occurring more than 12 months after completion of initial radiotherapy, with no systemic or local antitumor treatment during this interval.
- At least one measurable lesion according to RECIST v1.1.
Key exclusion criteria (20 listed)
- Patients with surgically resectable locally recurrent disease, including rT2 disease limited to the superficial parapharyngeal space and located more than 0.5 cm from the internal carotid artery, or rT3 disease limited to the floor of the sphenoid sinus and located more than 0.5 cm from the internal carotid artery and cavernous sinus.
- Nasopharyngeal necrosis, radiation-induced brain injury, severe cervical fibrosis, or other CTCAE v5.0 Grade ≥3 radiation-related complications, with extremely high radiotherapy risk as assessed by the investigator.
- Grade ≥2 peripheral neuropathy according to CTCAE v5.0.
- Receipt of systemic chemotherapy within 3 weeks before the first dose of study drug; small-molecule targeted therapy within 2 weeks or 5 half-lives, whichever is longer, before the first dose; antitumor biologic therapy, macromolecular targeted therapy, immunotherapy, or major surgery within 4 weeks before the first dose, except for minor surgery within 2 weeks with complete recovery.
- Residual toxicity from prior antitumor therapy, including immunotherapy, targeted therapy, chemotherapy, or radiotherapy, except alopecia, fatigue, and Grade 2 hypothyroidism, or clinically significant laboratory abnormalities greater than Grade 1 according to CTCAE v5.0.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Becotatug VedotinBecotatug vedotin will be administered at 2.0 mg/kg intravenously on Day 1 every 3 weeks for 2 cycles as induction therapy, in combination with a PD-1 monoclonal antibody. | Drug | Experimental group |
| ToripalimabToripalimab will be administered at 240 mg intravenously on Day 1 every 3 weeks. Toripalimab is one of the optional PD-1 monoclonal antibodies in this study and will be used as an alternative to camrelizumab, not in combination with camrelizumab. It will be given during induction therapy, concurrently with radiotherapy, and as maintenance therapy after radiotherapy until disease progression or unacceptable toxicity. | Drug | Experimental group |
| CamrelizumabCamrelizumab will be administered at 200 mg intravenously on Day 1 every 3 weeks. Camrelizumab is one of the optional PD-1 monoclonal antibodies in this study and will be used as an alternative to toripalimab, not in combination with toripalimab. It will be given during induction therapy, concurrently with radiotherapy, and as maintenance therapy after radiotherapy until disease progression or unacceptable toxicity. | Drug | Experimental group |
| Intensity-Modulated RadiotherapyIntensity-modulated radiotherapy will be delivered once daily, 5 days per week. Prescribed doses are 60 Gy in 27 fractions to PTVnx, 60-64 Gy in 27 fractions to PTVnd, and 54 Gy in 27 fractions to PTV1. | Drug | Experimental group |
Primary outcome
Objective response rate
Time frame: Baseline; end of 2 induction cycles (21 days/cycle); 8-12 weeks after radiotherapy; every 12 weeks through Month 24; then every 24 weeks thereafter until progression, new anticancer therapy, death, or study completion, up to 36months.
The proportion of participants who achieve a complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST v1.1, from the first dose until disease progression, initiation of new anticancer therapy, death, or the last tumor assessment, whichever occurs first.
10 secondary outcomes
Duration of Response (DoR)
Time frame: From first documented CR or PR until first documented disease progression or death, whichever occurs first, assessed up to 36 months.
Locoregional Recurrence-Free Survival (LRFS)
Time frame: From the first dose until the first documented locoregional recurrence/progression or death from any cause, whichever occurs first, assessed up to 36 months.
Treatment-Related Adverse Events
Time frame: From first dose to 90 days after last study treatment; late radiotherapy-related toxicities followed until Month 24 or study completion.
Overall Survival (OS)
Time frame: From the first dose until death from any cause, assessed up to 36 months.
12-Month Progression-Free Survival Rate
Time frame: From the first dose to 12 months.
24-Month Progression-Free Survival Rate
Time frame: From the first dose to 24 months.
Progression-Free Survival (PFS)
Time frame: From the first dose until the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first, assessed up to 36 months.
Disease Control Rate (DCR)
Time frame: Baseline; end of 2 induction cycles (21 days/cycle); 8-12 weeks after radiotherapy; every 12 weeks through Month 24; then every 24 weeks thereafter until progression, death, or study completion, up to 36 months.
Distant Metastasis-Free Survival (DMFS)
Time frame: From first dose until first documented distant metastasis or death, whichever occurs first, assessed up to 36 months.
Quality of Life (QoL)
Time frame: Baseline; end of 2 induction cycles (21 days/cycle); end of radiotherapy; 8-12 weeks after radiotherapy; every 12 weeks through Month 24; then every 24 weeks thereafter until study completion, up to 36 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No. Researchers who has been approved can share.
Related trials for Nasopharyngeal Carcinoma
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
Not yet recruitingObservational study
Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
Nasopharyngeal Carcinoma (NPC)
RecruitingPhase 1/2
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yi-Jun Hua, MD principal investigator
Sun Yat-sun University Cancer Center
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Becotatug Vedotin, Toripalimab and Camrelizumab in people with Nasopharyngeal Carcinoma, run by Sun Yat-sen University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yi-Jun Hua, MD (18820019088, huayj@sysucc.org.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective response rate (time frame: Baseline; end of 2 induction cycles (21 days/cycle); 8-12 weeks after radiotherapy; every 12 weeks through Month 24; then every 24 weeks thereafter until progression, new anticancer therapy, death, or study completion, up to 36months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.